Double-Punch combo tested to fight aggressive leukemia
NCT ID NCT03160079
Summary
This study tested a combination of two immunotherapy drugs, blinatumomab and pembrolizumab, for adults whose B-cell acute lymphoblastic leukemia had returned or did not respond to prior treatment. The main goal was to see if adding pembrolizumab improved the chances of achieving a deep remission compared to using blinatumomab alone. It involved 16 adult participants with a high amount of leukemia cells in their bone marrow.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UC Irvine Health Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCSF Comprehensive Cancer Center
San Francisco, California, 94143, United States
-
UCSF Fresno Community Cancer Institute
Clovis, California, 93611, United States
Conditions
Explore the condition pages connected to this study.